Market Research Logo
Region: Europe
Category: Country Overviews

Europe Country Overviews

(140 reports matching your criteria)
  • Belarus Pharmaceuticals and Healthcare Report Q2 2015

    ... two years. Furthermore, increased scrutiny by President Lukashenko over pharmaceutical imports indicates that Belarus may follow neighbouring Russia in instituting measures that favour the domestic industry and restrict the market for pharmaceutical imports. Headline Expenditure ... Read More

  • Estonia Pharmaceuticals and Healthcare Report Q2 2015

    ... jointly procure pharmaceuticals for their collective needs. Despite the small size of Estonia's pharmaceuticals industry, there is the potential for manufacturers to use the country as a low-cost export base, rather than focusing on the ... Read More

  • United Kingdom Pharmaceuticals and Healthcare Report Q2 2015

    ... is a key international player, and will continue to be for the foreseeable future. However, the climate of cost containment, coupled with patent expirations, will lower the overall value of the UK's drug market. Headline ... Read More

  • Ukraine Pharmaceuticals and Healthcare Report Q2 2015

    ... Eastern Ukraine and the severeerosion of consumer purchasing power resulting from a significant depreciation in the hryvnia. Withconsumer-spending the driving force behind pharmaceutical sales, the political and economic situation inUkraine will need to stabilise before ... Read More

  • Romania Pharmaceutical Report - Q4, 2014

    ... double-digit annual pace in Q4/2014 in RON terms. Sales of prescription based medicines (partly or fully subsidized) advanced by 9.6% y/y to RON2.4bn (€530mn), while OTC drug sales surged by 19.5% y/y over the quarter. ... Read More

  • France Pharmaceuticals and Healthcare Report Q2 2015

    ... capita spending levels on medicines. However, several cost-containment measures will continue to exert downward pressure on market growthover a multi-year horizon. On the upside, current macroeconomic trends, including low oil and food prices,should be net ... Read More

  • Romania Pharmaceuticals and Healthcare Report Q2 2015

    ... drive pharmaceuticalconsumption, but local regulatory factors such as revenue taxes will continue to present obstacles togrowth. Over the longer term, we expect the underfunding of the healthcare system to be addressed andgiven the country's ageing ... Read More

  • Bulgaria Pharmaceuticals and Healthcare Report Q2 2015

    ... healthcare financing, we holda more positive view for the long term development of the pharmaceutical & healthcare sector. Headline Expenditure Projections Pharmaceuticals: BGN2.50bn (USD1.71bn) in 2014 to BGN2.41bn (USD1.54bn) in 2015; -3.7% inlocal currency terms ... Read More

  • Germany Pharmaceuticals and Healthcare Report Q2 2015

    ... patented medicines. In spiteof this, additional restrictions on reimbursement, tempered by government's desire to preserve an industryintegral to Germany's positive balance of trade and international prestige, will nonetheless constrainrevenues and intensify already fierce competition amongst ... Read More

  • Czech Republic Pharmaceuticals and Healthcare Report Q2 2015

    ... decline. Indeed, thesechanges will help to provide for the growing demand for innovative drugs among the country's ageingpopulation. The healthcare spending of the Czech population remains superior to that of the less-developedmarkets of Eastern and ... Read More

  • Denmark Pharmaceuticals and Healthcare Report Q1 2015

    ... first time since 2009. Wemaintain our view that Denmark is an attractive market for drugmakers to operate in due to the country'shigh per-capita drug expenditure, transparent operating environment and strong regulatory climate.However, as the country's ... Read More

  • Romania Pharmaceutical Report - Q3, 2014

    ... as shown by official statistics. Imports dropped by 1.1% y/y to €1.5bn in January-July, after having increased by 7.8% y/y to € 2.7bn in full year 2013. Exports also declined by 10.5% y/y over the ... Read More

  • Poland Pharmaceuticals Report - 2014

    ... yet visibly, albeit slowly, recovering after the decline in 2012, when the entire pharma sector was affected by the price cut for reimbursed drugs, as part of the Reimbursed Act enforced and amended during the ... Read More

  • Pharmaceuticals and Healthcare Report - Greece Q4 2104

    ... The generic drug sector and private healthcare industrymay present some growth opportunities in the country. Headline Expenditure Projections Pharmaceuticals: EUR5.64bn (USD7.45bn) in 2013 to EUR5.28bn (USD7.07bn) in 2014; -6.5% inlocal currency terms and -5.1% in ... Read More

  • Pharmaceuticals and Healthcare Report - Czech Republic Q4 2014

    ... larger multinationals with competitive pressures expected tocontinue to favour those with scale. While we expect the Czech market to stabilise in 2014, we note thatdepreciatory pressure on the Czech koruna could see incomes decline for ... Read More

  • Pharmaceuticals and Healthcare Report - Denmark Q4 2014

    ... driven by its expanding aging population. However, this willsee the government continue to target the healthcare sector with cost-containment measures. Despite this,we believe Denmark will remain an attractive market for drugmakers to operate in due ... Read More

  • Pharmaceuticals and Healthcare Report - Finland Q4 2104

    ... we believe this will result in stronger downward price pressures onmedicines that treat long-term chronic diseases, with companies increasingly being required to prove thecost-effectiveness of innovative medicines in order to gain reimbursement. Headline Expenditure Projections ... Read More

  • Pharmaceuticals and Healthcare Report - Serbia Q4 2014

    ... Although criticised bythe media for its new policy of lowering medicine prices, Babic believes it means that the organisation isnot working for pharmaceutical companies but for the benefit of the Serbian people. The implementation ofthe ... Read More

  • Pharmaceuticals and Healthcare Report - Slovakia Q4 2014

    ... autumn this year. Medical fees byhospitals and doctors are symptomatic of the chronic inefficiency of healthcare funding within Slovakia. With the healthcare system set to come under the complete control of the Slovak state, funding ... Read More

  • Pharmaceuticals and Healthcare Report - Spain Q4 2014

    ... follow suit until 2018. Regardless of callsmade by companies for the implementation of a system that adequately rewards innovation and supportsinvestment in future medicines, the government will likely continue with its cost containment measures bytargeting ... Read More

  • Pharmaceuticals and Healthcare Report - Belarus Q4 2014

    ... Ukraine andRussia and absolute erosion of consumer purchasing power. Geopolitical tension between Russia andUkraine will continue to impact trading volumes in the region, with a full-blown conflict posing a seriousthreat to the Belarusian economy. Belarus ... Read More

  • Pharmaceuticals and Healthcare Report - Ukraine Q4 2014

    ... severe devaluation of the hryvnia inthe country, drugmakers can expect a challenging business environment as capital outflow restrictions havebeen recently implemented. Import taxes, pricing restrictions, and exchange rate volatility presentsignificant risks to drugmakers operating in ... Read More

  • Romania Pharmaceutical Report - Q2, 2014

    ... to RON 3bn (EUR 679.8mn) in Q2/2014, returning to growth after having declined on an annual basis for three consecutive quarters. In volume terms, the market also rose by 3.2% y/y in Q2, recovering from ... Read More

  • Pharmaceuticals and Healthcare Report - Netherlands Q4 2014

    ... austerity measures to meet the terms of EUbudget criteria and further restrictions on drug expenditure look likely, particularly on essential medicines. Although healthcare expenditure continues to increase (in local currency terms), we maintain our view ... Read More

  • Pharmaceuticals and Healthcare Report - Portugal - Q3 2014

    ... to growth in 2015, while pharmaceuticals will not return to growth until 2019. This isbecause while Portugal exited its bailout programme in May 2014 without the need for a new financialpackage, government austerity measures are ... Read More

1 2 3 5